Accès à distance ? S'identifier sur le proxy UCLouvain
Dose tailoring of dabigatran etexilate: obvious or excessive?
Primary tabs
Document type | Article de périodique (Journal article) – Synthèse de littérature |
---|---|
Access type | Accès restreint |
Publication date | 2015 |
Language | Anglais |
Journal information | "Expert Opinion on Drug Safety" - Vol. 14, no. 8, p. 1283-1289 (2015) |
Peer reviewed | yes |
Publisher | Informa Healthcare ((United Kingdom) London) |
issn | 1474-0338 |
e-issn | 1744-764X |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/MONT - Pôle Mont Godinne UCL - (MGD) Laboratoire de biologie clinique |
Keywords | Anticoagulant drugs ; Benefit–risk assessment ; Dabigatran etexilate ; Drug monitoring |
Links |
- Powell J. Robert, Are New Oral Anticoagulant Dosing Recommendations Optimal for All Patients?, 10.1001/jama.2015.59
- Lu Y., Branstad R., Karim R. M., Asinger R. W., Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation, 10.1111/jcpt.12207
- Legrand Matthieu, The Use of Dabigatran in Elderly Patients, 10.1001/archinternmed.2011.314
- McConeghy Kevin W., Bress Adam, Qato Dima M., Wing Coady, Nutescu Edith A., Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the FDA Adverse Event Reporting System during the First Year of Approval, 10.1002/phar.1415
- Southworth Mary Ross, Reichman Marsha E., Unger Ellis F., Dabigatran and Postmarketing Reports of Bleeding, 10.1056/nejmp1302834
- Hernandez Inmaculada, Baik Seo Hyon, Piñera Antonio, Zhang Yuting, Risk of Bleeding With Dabigatran in Atrial Fibrillation, 10.1001/jamainternmed.2014.5398
- Lauffenburger J. C., Farley J. F., Gehi A. K., Rhoney D. H., Brookhart M. A., Fang G., Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study, 10.1161/jaha.115.001798
- Huisman Menno V., Lip Gregory Y.H., Diener Hans C., Dubner Sergio J., Halperin Jonathan L., Ma Chang S., Rothman Kenneth J., Teutsch Christine, Zint Kristina, Ackermann Diana, Clemens Andreas, Bartels Dorothee B., Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation, 10.1016/j.ahj.2013.12.006
- Kakkar Ajay K., Mueller Iris, Bassand Jean-Pierre, Fitzmaurice David A., Goldhaber Samuel Z., Goto Shinya, Haas Sylvia, Hacke Werner, Lip Gregory Y.H., Mantovani Lorenzo G., Verheugt Freek W.A., Jamal Waheed, Misselwitz Frank, Rushton-Smith Sophie, Turpie Alexander G.G., International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD), 10.1016/j.ahj.2011.09.011
- Piccini Jonathan P., Fraulo Elizabeth S., Ansell Jack E., Fonarow Gregg C., Gersh Bernard J., Go Alan S., Hylek Elaine M., Kowey Peter R., Mahaffey Kenneth W., Thomas Laine E., Kong Melissa H., Lopes Renato D., Mills Roger M., Peterson Eric D., Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF, 10.1016/j.ahj.2011.07.001
- Stangier Joachim, Clemens Andreas, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, 10.1177/1076029609343004
- ten Cate Hugo, New oral anticoagulants: discussion on monitoring and adherence should start now!, 10.1186/1477-9560-11-8
- Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
- Chan N. C., Coppens M., Hirsh J., Ginsberg J. S., Weitz J. I., Vanassche T., Douketis J. D., Schulman S., Eikelboom J. W., Real-world variability in dabigatran levels in patients with atrial fibrillation, 10.1111/jth.12823
- Pare G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M. D., Axelsson T., Haertter S., Oldgren J., Reilly P., Siegbahn A., Syvanen A.-C., Wadelius C., Wadelius M., Zimdahl-Gelling H., Yusuf S., Wallentin L., Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding, 10.1161/circulationaha.112.001233
- Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
- Baglin Trevor, Keeling David, Kitchen Steve, Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology, 10.1111/bjh.12052
- Douxfils J, Biomed Res Int (2014)
- Hapgood G., Butler J., Malan E., Chunilal S., Tran H., The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples : , 10.1160/th13-04-0301
- Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
- Douxfils J., Lessire S., Dincq A.-S., Hjemdahl P., Rönquist-Nii Y., Pohanka A., Gourdin M., Chatelain B., Dogné J.-M., Mullier F., Estimation of dabigatran plasma concentrations in the perioperative setting : An ex vivo study using dedicated coagulation assays, 10.1160/th14-09-0808
- Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, 10.1093/europace/eut083
- BOUNAMEAUX H., REBER G., New oral antithrombotics: a need for laboratory monitoring. Against, 10.1111/j.1538-7836.2010.03759.x
- MISMETTI P., LAPORTE S., New oral antithrombotics: a need for laboratory monitoring. For, 10.1111/j.1538-7836.2010.03764.x
- Rao Rama B., Regarding the Effect of Dabigatran Plasma Concentrations, 10.1016/j.jacc.2014.02.610
- Douxfils J., Chatelain B., Dogné J.-M., Mullier F., Real-world variability in dabigatran levels in patients with atrial fibrillation: comment, 10.1111/jth.12880
- Ruff Christian T, Giugliano Robert P, Braunwald Eugene, Morrow David A, Murphy Sabina A, Kuder Julia F, Deenadayalu Naveen, Jarolim Petr, Betcher Joshua, Shi Minggao, Brown Karen, Patel Indravadan, Mercuri Michele, Antman Elliott M, Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial, 10.1016/s0140-6736(14)61943-7
Bibliographic reference | Douxfils, Jonathan ; Mullier, François ; Dogné, Jean-Michel. Dose tailoring of dabigatran etexilate: obvious or excessive?. In: Expert Opinion on Drug Safety, Vol. 14, no. 8, p. 1283-1289 (2015) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/160885 |